US 12,467,064 B2
Artificial expression constructs for selectively modulating gene expression in interneurons
Jonathan Ting, Lake Forest Park, WA (US); Boaz P. Levi, Seattle, WA (US); John K. Mich, Seattle, WA (US); Edward Sebastian Lein, Mercer Island, WA (US); and Franck Kalume, Bothell, WA (US)
Assigned to Allen Institute, Seattle, WA (US); and Seattle Children's Hospital, Seattle, WA (US)
Appl. No. 17/283,232
Filed by Allen Institute, Seattle, WA (US); and Seattle Children's Hospital, Seattle, WA (US)
PCT Filed Oct. 3, 2019, PCT No. PCT/US2019/054539
§ 371(c)(1), (2) Date Apr. 6, 2021,
PCT Pub. No. WO2020/076614, PCT Pub. Date Apr. 16, 2020.
Claims priority of provisional application 62/810,281, filed on Feb. 25, 2019.
Claims priority of provisional application 62/749,012, filed on Oct. 22, 2018.
Claims priority of provisional application 62/742,835, filed on Oct. 8, 2018.
Prior Publication US 2021/0348195 A1, Nov. 11, 2021
Int. Cl. C12N 15/86 (2006.01); A01K 67/0278 (2024.01); A61K 35/30 (2015.01); C12N 5/0793 (2010.01)
CPC C12N 15/86 (2013.01) [A01K 67/0278 (2013.01); A61K 35/30 (2013.01); C12N 5/0619 (2013.01); A01K 2217/052 (2013.01); A01K 2227/105 (2013.01); A01K 2227/106 (2013.01); C12N 2510/00 (2013.01); C12N 2750/14043 (2013.01)] 18 Claims
 
1. An artificial expression construct comprising (i) a concatemer comprising 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of a sequence consisting of SEQ ID NO: 2 or SEQ ID NO: 6; (ii) a promoter; and (iii) a coding sequence.